{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:39Z","timestamp":1792008099151,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The progression of chronic kidney disease (CKD) cannot be completely inhibited. We first explored factors contributing to CKD progression in patients with CKD in a prospective observational study. In the next phase, we focused on the effects of aldosterone, conducting a single-blinded placebo-controlled study using the selective mineralocorticoid receptor antagonist (MRA), eplerenone (25\u00a0mg\/day). We recruited patients with CKD stage 2 and 3 whose plasma aldosterone concentration was above 15\u00a0ng\/dL based on the prior data of a prospective observational study. In the CKD cohort study (n\u2009=\u2009141), baseline plasma aldosterone concentration was identified as an independent contributory factor for the future rate of change in estimated glomerular filtration rate (eGFR). When the cut-off value for aldosterone was set at 14.5\u00a0ng\/dL, the decline rate was significantly higher in patients with higher plasma aldosterone concentration (\u2212\u20091.22\u2009\u00b1\u20090.39\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>\/year vs. 0.39\u2009\u00b1\u20090.40\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>\/year, <jats:italic>p<\/jats:italic>\u2009=\u20090.0047). In the final intervention study, in the eplerenone group, eGFR dropped at 6\u00a0months after the initiation of the study, and thereafter eGFR was maintained until the end of the study. At 24\u00a0months and 36\u00a0months, eGFR was significantly higher in the eplerenone group than in the placebo group. In conclusion, MRA can be an effective strategy in preventing CKD progression, especially in patients with high plasma aldosterone.<\/jats:p>","DOI":"10.1038\/s41598-020-73638-4","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T10:04:27Z","timestamp":1601978667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial"],"prefix":"10.1038","volume":"10","author":[{"given":"Hitoshi","family":"Minakuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wakino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Urai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Kurokochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirobumi","family":"Tokuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"73638_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.ajkd.2018.01.002","volume":"71","author":"R Saran","year":"2018","unstructured":"Saran, R. et al. Epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 71, 501 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"73638_CR2","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha, R. et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141, 3871\u20133878 (2000).","journal-title":"Endocrinology"},{"key":"73638_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1053\/snep.2001.26797","volume":"21","author":"TH Hostetter","year":"2001","unstructured":"Hostetter, T. H., Rosenberg, M. E., Ibrahim, H. N. & Juknevicius, I. Aldosterone in progressive renal disease. Semin. Nephrol. 21, 573\u2013579 (2001).","journal-title":"Semin. Nephrol."},{"key":"73638_CR4","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","volume":"14","author":"TH Hostetter","year":"2003","unstructured":"Hostetter, T. H. & Ibrahim, H. N. Aldosterone in chronic kidney and cardiac disease. J. Am. Soc. Nephrol. 14, 2395\u20132401 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"73638_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.semnephrol.2014.04.006","volume":"34","author":"JS Hirsch","year":"2014","unstructured":"Hirsch, J. S., Drexler, Y. & Bomback, A. S. Aldosterone blockade in chronic kidney disease. Semin. Nephrol. 34, 307\u2013322 (2014).","journal-title":"Semin. Nephrol."},{"key":"73638_CR6","doi-asserted-by":"crossref","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet349, 1857\u20131863 (1997).","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"73638_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"73638_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"E Greene","year":"1996","unstructured":"Greene, E., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063\u20131068 (1996).","journal-title":"J. Clin. Invest."},{"key":"73638_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hene","year":"1982","unstructured":"Hene, R. J., Boer, P., Koomans, H. A. & Dorhout Mees, E. J. Plasma aldosterone concentration in chronic renal failure. Kidney Int. 21, 98\u2013101 (1982).","journal-title":"Kidney Int."},{"key":"73638_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ki.1978.114","volume":"14","author":"T Berl","year":"1978","unstructured":"Berl, T., Katz, F. H., Henrich, W. L., de Torrente, A. & Schrier, R. W. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 14, 228\u2013235 (1978).","journal-title":"Kidney Int."},{"key":"73638_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","volume":"21","author":"R Rachmani","year":"2004","unstructured":"Rachmani, R. et al. The effects of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetes Med. 21, 471\u2013475 (2004).","journal-title":"Diabetes Med."},{"key":"73638_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato, A., Hayashi, K. & Saruta, T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41, 64\u201368 (2003).","journal-title":"Hypertension"},{"key":"73638_CR13","first-page":"CD007004","volume":"4","author":"D Bolignano","year":"2014","unstructured":"Bolignano, D., Palmer, S. C., Navaneethan, S. D. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 4, CD007004 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"73638_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie, G. et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 17, 127 (2016).","journal-title":"BMC Nephrol."},{"key":"73638_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"BL Bakris","year":"2019","unstructured":"Bakris, B. L. et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 50, 333\u2013344 (2019).","journal-title":"Am J Nephrol."},{"key":"73638_CR16","unstructured":"Schaffer R. Finerenone delays diabetic kidney disease progression: FIDELIO-DKD. Healio and Endocrine Today2019, July 10, 2020."},{"key":"73638_CR17","doi-asserted-by":"crossref","unstructured":"Heerspink, H. J., Kr\u00f6pelin, T. F., Hoekman, J. & de Zeeuw, D. Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J. Am. Soc. Nephrol.26, 2055-2064 (2015).","DOI":"10.1681\/ASN.2014070688"},{"key":"73638_CR18","first-page":"CD008996","volume":"2","author":"TS Tam","year":"2017","unstructured":"Tam, T. S. et al. Eplerenone for hypertension. Cochrane Database Syst Rev. 2, CD008996 (2017).","journal-title":"Cochrane Database Syst Rev."},{"key":"73638_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene, E. L., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063\u20131068 (1996).","journal-title":"J. Clin. Invest."},{"key":"73638_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hen\u00e9","year":"1982","unstructured":"Hen\u00e9, R. J., Boer, P., Koomans, H. A. & Mees, E. J. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 21, 98\u2013101 (1982).","journal-title":"Kidney Int."},{"key":"73638_CR21","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116\u20132123 (2006).","journal-title":"Kidney Int."},{"key":"73638_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/ki.1992.45","volume":"41","author":"ZY Quan","year":"1992","unstructured":"Quan, Z. Y., Walser, M. & Hill, G. S. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 41, 326\u2013333 (1992).","journal-title":"Kidney Int."},{"key":"73638_CR23","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","volume":"112","author":"M Quinkler","year":"2005","unstructured":"Quinkler, M. et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112, 1435\u20131443 (2005).","journal-title":"Circulation"},{"key":"73638_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijcard.2015.05.125","volume":"200","author":"S Bianchi","year":"2015","unstructured":"Bianchi, S., Batini, V. & Bigazzi, R. The renal effects of mineralocorticoid receptor antagonists. Int. J. Cardiol. 200, 20\u201324 (2015).","journal-title":"Int. J. Cardiol."},{"key":"73638_CR25","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"Arima, S. et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14, 2255\u20132263 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"73638_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal, J., Girerd, S. & Jaisser, F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 96, 302\u2013319 (2019).","journal-title":"Kidney Int."},{"key":"73638_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou, A., Pedagogos, E., MacGregor, L. & Becker, G. J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 1, 256\u2013262 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"73638_CR28","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker, A. H. et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J. Hypertens. 24, 2285\u20132292 (2006).","journal-title":"J. Hypertens."},{"key":"73638_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940\u2013951 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"73638_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou, A. & Becker, G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. 345, 925\u2013926 (2001).","journal-title":"N. Engl. J. Med."},{"key":"73638_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","volume":"46","author":"S Bianchi","year":"2005","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am. J. Kidney. Dis. 46, 45\u201351 (2005).","journal-title":"Am. J. Kidney. Dis."},{"key":"73638_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","volume":"73","author":"NC Edwards","year":"2012","unstructured":"Edwards, N. C. et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br. J. Clin. Pharmacol. 73, 447\u2013454 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"73638_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","volume":"22","author":"MH Schwenk","year":"2015","unstructured":"Schwenk, M. H., Hirsch, J. S. & Bomback, A. S. Aldosterone blockade in CKD: emphasis on pharmacology. Adv. Chronic Kidney Dis. 22, 123\u2013132 (2015).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"73638_CR34","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group. N. Engl. J. Med. 329, 1456\u20131462 (1993).","journal-title":"N. Engl. J. Med."},{"key":"73638_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/01.HYP.0000205224.58715.cc","volume":"47","author":"BM Schmidt","year":"2006","unstructured":"Schmidt, B. M. et al. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 47, 650\u2013655 (2006).","journal-title":"Hypertension"},{"key":"73638_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/01.HYP.0000111138.78714.1a","volume":"43","author":"S Arima","year":"2004","unstructured":"Arima, S. et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43, 352\u2013357 (2004).","journal-title":"Hypertension"},{"key":"73638_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/01.fjc.0000211738.63207.c3","volume":"47","author":"Y Hashikabe","year":"2006","unstructured":"Hashikabe, Y., Suzuki, K., Jojima, T., Uchida, K. & Hattori, Y. Aldosterone impairs vascular endothelial cell function. J. Cardiovasc. Pharmacol. 47, 609\u2013613 (2006).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"73638_CR38","first-page":"269","volume":"6","author":"MA Silva","year":"2015","unstructured":"Silva, M. A. et al. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO\/GC signaling. Front. Physiol. 6, 269 (2015).","journal-title":"Front. Physiol."},{"key":"73638_CR39","doi-asserted-by":"publisher","first-page":"F1473","DOI":"10.1152\/ajprenal.00437.2010","volume":"299","author":"D Ackermann","year":"2010","unstructured":"Ackermann, D. et al. In vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: differential effect of corticosteroids along the distal tubule. Am. J. Physiol. Renal Physiol. 299, F1473-1485 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"73638_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF00663911","volume":"399","author":"G El Mernissi","year":"1983","unstructured":"El Mernissi, G. & Doucet, A. Short-term effects of aldosterone and dexamethasone on Na-K-ATPase along the rabbit nephron. Pflugers Arch. 399, 147\u2013151 (1983).","journal-title":"Pflugers Arch."},{"key":"73638_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11010-007-9680-6","volume":"310","author":"V Pinto","year":"2008","unstructured":"Pinto, V., Pinho, M. J., Hopfer, U., Jose, P. A. & Soares-da-Silva, P. Oxidative stress and the genomic regulation of aldosterone-stimulated NHE1 activity in SHR renal proximal tubular cells. Mol. Cell. Biochem. 310, 191\u2013201 (2008).","journal-title":"Mol. Cell. Biochem."},{"key":"73638_CR42","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.bbamcr.2013.05.009","volume":"1833","author":"SA Salyer","year":"2013","unstructured":"Salyer, S. A. et al. Aldosterone regulates Na(+), K(+) ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor. Biochim. Biophys. Acta. 1833, 2143\u20132152 (2013).","journal-title":"Biochim. Biophys. Acta."},{"key":"73638_CR43","doi-asserted-by":"publisher","first-page":"69309","DOI":"10.18632\/oncotarget.12503","volume":"7","author":"B Wang","year":"2016","unstructured":"Wang, B. et al. Overexpressed cyclophilin B suppresses aldosterone-induced proximal tubular cell injury both in vitro and in vivo. Oncotarget 7, 69309\u201369320 (2016).","journal-title":"Oncotarget"},{"key":"73638_CR44","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi, E. R. et al. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791\u20131800 (2003).","journal-title":"Kidney Int."},{"key":"73638_CR45","doi-asserted-by":"publisher","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","volume":"6","author":"L Boesby","year":"2011","unstructured":"Boesby, L., Elung-Jensen, T., Klausen, T. W., Strandgaard, S. & Kamper, A. L. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease A randomized cross-over study. PLoS ONE 6, e26904 (2011).","journal-title":"PLoS ONE"},{"key":"73638_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/jcm7110459","volume":"7","author":"CT Yang","year":"2018","unstructured":"Yang, C. T., Kor, C. T. & Hsieh, Y. P. Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J Clin Med. 7, 459 (2018).","journal-title":"J Clin Med."},{"key":"73638_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10157-006-0453-4","volume":"11","author":"E Imai","year":"2007","unstructured":"Imai, E. et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin. Exp. Nephrol. 11, 41\u201350 (2007).","journal-title":"Clin. Exp. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73638-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73638-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73638-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:32:12Z","timestamp":1670358732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73638-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73638"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73638-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16626"}}